Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2015: Novel combination approaches for multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.15
Views: 3509
Rating:

Prof Marivi Mateos, Prof Sagar Lonial, Dr Torben Plesner, Prof Meletios Dimopoulos

Prof Marivi Mateos (University Hospital of Salamanca, Salamanca, Spain), Prof Meletios Dimopoulos (University of Athens, Athens, Greece), Dr Torben Plesner (Vejle Hospital, University of Southern Denmark, Vejle, Denmark) and Prof Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discuss the latest data on multiple myeloma from ASH 2015.

The panel discuss novel combination approaches to treat multiple myeloma, the role of monoclonal antibodies as single agents or in combination, and how to manage potential side effects.

During the discussion the experts talk about several studies including the recent findings of a phase III trial looking at daratumumab monotherapy in heavily pretreated patients with relapsed or refractory multiple myeloma.

Results from an update of the ELOQUENT-2 study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed or refractory multiple myeloma and the updated results of the Phase I GEN503 study are also highlighted, both of which made an impact at the meeting.

They also discuss a study investigating the use of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed refractory multiple myeloma. The combination of daratumumab with pomalidomide and dexamethasone in the same setting is also discussed.

Finally they look at what the future may hold in the ever-changing treatment landscape of multiple myeloma.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation